Page 87 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

3q26 as a prognostic biomarker
4
85
Study
Baseline pathology
No. of cases
Specimen Follow-up term
Follow-up measure
HPV tested?
Distinction polyploidy/ gain
No. of evaluated cells
Cutoff
Cases with gain
Disease outcome
Rodolakis, 2012
CIN1 or koilocytosis, histological diagnosis
40
(31 LSIL and 9 ASCUSc)
Liquid - based cytology
11-22m
Cytology and colposcopy with biopsy
No
Yes, tetraploidy ruled out by defining gain as >4 signals
800 cells with the highest number of signals
>4 signals in ≥ 2 cells OR >4 signals in ≥ 1 cell and 10 cells with 4 3q signals and 2 centromere 7 signals (4-2), pragmatic
8/40 (20%)
Non-progression: 37/40 (93%) Progression:
3/40 (8%)
Obermann, 2013
LSIL cytology 132
Liuid- based cytology
Min 6m
Cytology followed by colposcopy with biopsy on indication
Yes
No
Up to 50 cells
> 2 signals in ≥ 10% of cells, pragmatic
LSIL: 31% (absolute numbers not report- ed)
Regression : 67/132 (51%) Persistence : 55/132 (42%) Progression: 10/132 (8%)
Li, 2014
CIN 1, histological diagnosis
74
Liquid - based cytology
24m
12m: HPV test
24m: colposcopy with biopsy and HPV test
Yes
No
100 cells
>2 signals in > 6% cells (based on mean gain + 3SD of control population)
23/74 (31%)
Regression: 42/74 (57%) Persistence: 25/74 (34%) Progression: 7/74 (9%)
table continues